S&P 500   4,689.67 (+2.13%)
DOW   35,747.90 (+1.48%)
QQQ   397.89 (+3.03%)
AAPL   170.74 (+3.28%)
MSFT   334.84 (+2.65%)
FB   323.83 (+1.87%)
GOOGL   2,935.51 (+2.53%)
AMZN   3,540.00 (+3.29%)
TSLA   1,046.83 (+3.75%)
NVDA   320.58 (+6.73%)
BABA   125.30 (+1.38%)
NIO   33.18 (+2.60%)
CGC   10.80 (+6.40%)
AMD   144.71 (+4.06%)
GE   97.96 (+2.03%)
MU   86.49 (+4.90%)
T   23.09 (-0.82%)
F   19.86 (+3.33%)
DIS   150.24 (-0.09%)
PFE   51.47 (-0.02%)
AMC   31.10 (+8.02%)
ACB   6.42 (+7.54%)
BA   210.42 (+2.21%)
S&P 500   4,689.67 (+2.13%)
DOW   35,747.90 (+1.48%)
QQQ   397.89 (+3.03%)
AAPL   170.74 (+3.28%)
MSFT   334.84 (+2.65%)
FB   323.83 (+1.87%)
GOOGL   2,935.51 (+2.53%)
AMZN   3,540.00 (+3.29%)
TSLA   1,046.83 (+3.75%)
NVDA   320.58 (+6.73%)
BABA   125.30 (+1.38%)
NIO   33.18 (+2.60%)
CGC   10.80 (+6.40%)
AMD   144.71 (+4.06%)
GE   97.96 (+2.03%)
MU   86.49 (+4.90%)
T   23.09 (-0.82%)
F   19.86 (+3.33%)
DIS   150.24 (-0.09%)
PFE   51.47 (-0.02%)
AMC   31.10 (+8.02%)
ACB   6.42 (+7.54%)
BA   210.42 (+2.21%)
S&P 500   4,689.67 (+2.13%)
DOW   35,747.90 (+1.48%)
QQQ   397.89 (+3.03%)
AAPL   170.74 (+3.28%)
MSFT   334.84 (+2.65%)
FB   323.83 (+1.87%)
GOOGL   2,935.51 (+2.53%)
AMZN   3,540.00 (+3.29%)
TSLA   1,046.83 (+3.75%)
NVDA   320.58 (+6.73%)
BABA   125.30 (+1.38%)
NIO   33.18 (+2.60%)
CGC   10.80 (+6.40%)
AMD   144.71 (+4.06%)
GE   97.96 (+2.03%)
MU   86.49 (+4.90%)
T   23.09 (-0.82%)
F   19.86 (+3.33%)
DIS   150.24 (-0.09%)
PFE   51.47 (-0.02%)
AMC   31.10 (+8.02%)
ACB   6.42 (+7.54%)
BA   210.42 (+2.21%)
S&P 500   4,689.67 (+2.13%)
DOW   35,747.90 (+1.48%)
QQQ   397.89 (+3.03%)
AAPL   170.74 (+3.28%)
MSFT   334.84 (+2.65%)
FB   323.83 (+1.87%)
GOOGL   2,935.51 (+2.53%)
AMZN   3,540.00 (+3.29%)
TSLA   1,046.83 (+3.75%)
NVDA   320.58 (+6.73%)
BABA   125.30 (+1.38%)
NIO   33.18 (+2.60%)
CGC   10.80 (+6.40%)
AMD   144.71 (+4.06%)
GE   97.96 (+2.03%)
MU   86.49 (+4.90%)
T   23.09 (-0.82%)
F   19.86 (+3.33%)
DIS   150.24 (-0.09%)
PFE   51.47 (-0.02%)
AMC   31.10 (+8.02%)
ACB   6.42 (+7.54%)
BA   210.42 (+2.21%)
NASDAQ:MDGS

Medigus Stock Forecast, Price & News

$1.13
+0.05 (+4.63%)
(As of 12/7/2021 12:36 PM ET)
Add
Compare
Today's Range
$1.12
$1.14
50-Day Range
$1.08
$1.58
52-Week Range
$1.05
$3.77
Volume
2,301 shs
Average Volume
2.00 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive MDGS News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigus and its competitors with MarketBeat's FREE daily newsletter.


Medigus logo

About Medigus

Medigus Ltd. engages in research and development of medical treatment for the gastrointestinal tract. Its product is the MUSE system, an endoscopic device to perform Transoral Fundoplication for the treatment of gastroesophageal reflux disease. The company was founded by Elazar Sonnenschein on December 9, 1999 and is headquartered in Omer, Israel.

Headlines

Medigus Filed a $3 Million Buyback Program - GlobeNewswire
December 1, 2021 |  globenewswire.com
Medigus Filed a $3 Million Buyback Program
December 1, 2021 |  finance.yahoo.com
Medigus Ltd. (NASDAQ:MDGS) Sees Significant Growth in Short Interest
November 29, 2021 |  americanbankingnews.com
Short Interest in Medigus Ltd. (NASDAQ:MDGS) Drops By 21.7%
November 20, 2021 |  americanbankingnews.com
Form 6-K Medigus Ltd. For: Nov 05 - StreetInsider.com
November 5, 2021 |  streetinsider.com
Form 6-K Medigus Ltd. For: Nov 02 - StreetInsider.com
November 2, 2021 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDGS
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Medigus (NASDAQ:MDGS) Frequently Asked Questions

Are investors shorting Medigus?

Medigus saw a increase in short interest in November. As of November 15th, there was short interest totaling 152,400 shares, an increase of 122.2% from the October 31st total of 68,600 shares. Based on an average daily trading volume, of 745,800 shares, the short-interest ratio is presently 0.2 days. Approximately 0.8% of the company's stock are sold short.
View Medigus' Short Interest
.

Who are Medigus' key executives?

Medigus' management team includes the following people:
  • Liron Carmel, Chief Executive Officer
  • Tali Dinar, Chief Financial Officer
  • Aviel Roy-Shapira, Medical Director
  • Daniel H. Spira, Internal Auditor

What other stocks do shareholders of Medigus own?

What is Medigus' stock symbol?

Medigus trades on the NASDAQ under the ticker symbol "MDGS."

Who are Medigus' major shareholders?

Medigus' stock is owned by a number of institutional and retail investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (0.00%) and Citadel Advisors LLC (0.00%).

Which institutional investors are selling Medigus stock?

MDGS stock was sold by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd., and Citadel Advisors LLC.

How do I buy shares of Medigus?

Shares of MDGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medigus' stock price today?

One share of MDGS stock can currently be purchased for approximately $1.13.

How many employees does Medigus have?

Medigus employs 2,020 workers across the globe.

What is Medigus' official website?

The official website for Medigus is www.medigus.com.

Where are Medigus' headquarters?

How can I contact Medigus?

Medigus' mailing address is Building 7A, Omer Industrial Park, Pob 3030, Omer 8496500. The company can be reached via phone at (728) 646-6880.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.